Vaccine News and Research

Latest Vaccine News and Research

Researchers figure out way to disable a part of SARS virus

A Purdue University-led research team has figured out how to disable a part of the SARS virus responsible for hiding it from the immune system; a critical step in developing a vaccine against the deadly disease.

4 Jun 2014

Salk Institute receives $25 million for cutting-edge biological research

The Salk Institute for Biological Studies has received a $25 million gift from San Diego philanthropist and former Salk trustee Conrad T. Prebys to support cutting-edge biological research on a wide range of diseases.

3 Jun 2014

AMRI agrees to acquire OsoBio for $110 million

AMRI today announced that it has signed a definitive agreement to acquire all of the outstanding membership interests of Oso Biopharmaceuticals Manufacturing, LLC for $110 million in cash.

2 Jun 2014

Updated data from ImmunoCellular ICT-107 trial in patients with newly diagnosed GBM presented at ASCO 2014

ImmunoCellular Therapeutics, Ltd. announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 American Society for Clinical Oncology (ASCO) annual meeting in Chicago.

2 Jun 2014

Immune system-boosting therapy slows recurrence of glioblastoma multiforme

A multicenter team of investigators, led by researchers from the Cedars-Sinai Department of Neurosurgery, the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Dana-Farber Cancer Institute in Boston, have found in a Phase II clinical trial that an immune system-boosting therapy slowed the recurrence of glioblastoma multiforme, or GBM, the most common and deadly malignant brain tumor.

2 Jun 2014

Morphogenesis announces publication of new book, Cancer Vaccines: Methods and Protocols

Drs. Michael J.P. Lawman and Patricia D. Lawman, founders of the Tampa-based biotech firm Morphogenesis Inc., announce the publication of "Cancer Vaccines: Methods and Protocols," the most definitive work to date in the promising field of cancer vaccines.

31 May 2014

Astellas seeks marketing approval for Flublok recombinant influenza vaccine in Japan

Protein Sciences Corporation announced today that Astellas Pharma has submitted an application for marketing approval of recombinant influenza HA vaccine ASP7374 (marketed as Flublok® in the United States by Protein Sciences) to the Ministry of Health, Labour and Welfare in Japan for the prevention of influenza.

31 May 2014

Inovio Pharmaceuticals’ reverse stock split to become effective on June 5, 2014

Inovio Pharmaceuticals, Inc. today announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014.

30 May 2014

Novozymes Biopharma to assess novel subunit vaccine candidate using Veltis technology

Novozymes Biopharma has entered a new collaborative research agreement with one of the world’s top vaccine companies. The partnership will enable the company to evaluate Novozymes Biopharma's modified recombinant human albumin (rAlbumin) Veltis technology, to assess the dosing and performance of a novel subunit antigen vaccine candidate.

30 May 2014

TSRI scientists receive more than $13M to design effective HIV vaccine

A team led by scientists at The Scripps Research Institute (TSRI) has received a grant of more than $13 million from the National Institute of Allergy and Infectious Disease of the National Institutes of Health to study antibodies to the human immunodeficiency virus (HIV)—which will play an essential role in the creation of any effective vaccine against HIV.

30 May 2014

New approach could lead to more effective HIV vaccine

Using a genetically modified form of the HIV virus, a team of University of Nebraska-Lincoln scientists has developed a promising new approach that could someday lead to a more effective HIV vaccine.

30 May 2014

TSRI scientists receive $13M grant to create effective vaccine against HIV

A team led by scientists at The Scripps Research Institute (TSRI) has received a grant of more than $13 million from the National Institute of Allergy and Infectious Disease of the National Institutes of Health to study antibodies to the human immunodeficiency virus (HIV)-which will play an essential role in the creation of any effective vaccine against HIV.

30 May 2014

Vaccine News and Research

Latest Vaccine News and Research

Researchers figure out way to disable a part of SARS virus

Salk Institute receives $25 million for cutting-edge biological research

AMRI agrees to acquire OsoBio for $110 million

Updated data from ImmunoCellular ICT-107 trial in patients with newly diagnosed GBM presented at ASCO 2014

Immune system-boosting therapy slows recurrence of glioblastoma multiforme

Morphogenesis announces publication of new book, Cancer Vaccines: Methods and Protocols

Astellas seeks marketing approval for Flublok recombinant influenza vaccine in Japan

Inovio Pharmaceuticals’ reverse stock split to become effective on June 5, 2014

Novozymes Biopharma to assess novel subunit vaccine candidate using Veltis technology

TSRI scientists receive more than $13M to design effective HIV vaccine

New approach could lead to more effective HIV vaccine

TSRI scientists receive $13M grant to create effective vaccine against HIV

Biomedical scientists explore mechanisms of novel treatments for HCV

Ebola research: an interview with Professor Easton, University of Warwick

Inovio announces positive results on DNA-based monoclonal antibody therapy targeting CHIKV

Employers to implement mandatory influenza vaccination policies for health care workers

Peptide antibodies hit immune-response-stifling MDSCs without harming other vital cells

Lyme activists demand Congressional investigation of corruption within CDC, IDSA, and vaccine industry

Inovio Pharmaceuticals proposes 1-for-4 reverse split of common stock

Researchers uncover potential vaccine that can stop malaria parasites from multiplying

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in